Chinese Pharma 2024 - English Language

The annual report on the most valuable and strongest Chinese pharma brands

Sinopharm leads as the most valuable Chinese pharma brand ranked, Guangzhou Pharmaceutical tops Traditional Chinese Medicine ranking 

• Guangzhou Pharmaceutical and SPH also retain their spots as the second and third most valuable Chinese pharma brands ranked, respectively 

• Tong Ren Tang catapults up to become this year’s strongest Chinese pharma brand ranked 

Sinopharm holds on to its crown as the most valuable Chinese pharma brand ranked this year – according to a new report by Brand Finance, despite a slight decline in its brand value by 6% to USD3.6 billion.

Guangzhou Pharmaceutical and SPH also retain their spots as the second and third most valuable Chinese pharma brands ranked, respectively 

Guangzhou Pharmaceutical retained its second placing among the 15 most valuable Chinese pharma brands ranked, recording a brand value increase of 11% to USD2.5 billion while SPH has also kept its podium position among the top three most valuable Chinese pharma brands, only seeing a minor slip in its brand value by 1% to USD1.4 billion. 

In Brand Finance’s secondary ranking specifically focusing on TCM brands, Guangzhou Pharmaceutical has once again emerged as the most valuable TCM brand for the fourth consecutive year. This is followed by Yunnan Baiyao (brand value down 0.5% to USD822 million) remaining at the second spot and CR SANJIU (brand value up 12% to USD340 million) rising to third place. Tong Ren Tang (brand value up 17% to USD325 million) and Pien Tze Huang (brand value down 11% to USD278 million) are fourth and fifth respectively in the top five most valuable TCM brands ranked. 

Tong Ren Tang catapults up to become this year’s strongest Chinese pharma brand ranked 

Tong Ren Tang is also this year’s strongest Chinese pharma brand ranked, clinching a brand strength rating of AAA- and a Brand Strength Index (BSI) score of 80.9 out of 100. The top five is completed by 2023’s strongest Yunnan Baiyao (BSI 79.8), Guangzhou Pharmaceutical (BSI 70.9), CR SANJIU (BSI 69.2) and Pien Tze Huang (67.3).  

Brand Finance’s latest research in this sector shows that TCM brands continued to remain well received by consumers with Yunnan Baiyao leading for awareness and familiarity with 97% and 91% respectively, followed by Tong Ren Tang with 94% and 82%. The same brands, with the addition of Guangzhou Pharmaceutical also take up three of the top five Chinese pharma brands with the highest levels of brand consideration. 

"Research and development among Chinese pharma brands continues to rise, with the market bolstered by factors like economic growth, health awareness, urbanisation and chronic diseases. With support from locals, TCM brands continue to thrive, although Western Medicines are also widely used and not very far behind.” 

Scott Chen, Managing Director, Brand Finance China